Track Categories

The track category is the heading under which your abstract will be reviewed and later published in the conference printed matters if accepted. During the submission process, you will be asked to select one track category for your abstract.

Biomarker is the indicator   that can be accurately measured as signal of normal biological functioning, pathogenic paths or a drug response to a therapeutic drug mediation. Biomarkers are usually in molecular form. Biomarkers take place in various body functions, including disease diagnosis and prognosis, prediction and calculation of treatment response, and safety estimation. These  Biomarkers are  being developed and confirmed to be used in drug  development, and to support approval of drug products. 

 

  • Track 1-1Nucleic acid biomarkers
  • Track 1-2Protein Biomarkers
  • Track 1-3Lipid biomarkers
  • Track 1-4Small molecule biomarkers
  • Track 1-5neurological disorders

Molecular biomarkers defined as biomarkers that can be discovered using basic and acceptable platforms such as genomics and proteomics. Apart from genomics and proteomics platforms, biomarker assay techniques like metabolomics, lipidomics, glycemics, and secretomics are the most commonly used as techniques in identification of biomarkers. Molecular biomarkers are classified into Pathological biomarkers, Nucleic acid biomarkers, Insilco biomarkers, Glycoprotein biomarkers & Imaging biomarkers based on their structure and functioning. These such biomarkers can be tested in non-obtrusively gathered bio-fluids like blood or serum.

 

  • Track 2-1Pathological biomarkers
  • Track 2-2Imaging biomarkers
  • Track 2-3Genetic biomarkers
  • Track 2-4Glycoprotien biomarkers
  • Track 2-5In silico biomarkers
  • Track 2-6Serum testing
  • Track 2-7Mapping of genetic markers

Biomarker discovery requires sure identification of a biomarker with real-time quantitative information to indicate proteins  which are altering to a statistically applicable degree in response to disease. The discovery of biomarkers has been developed a  new  strategies from the initial stages. In the first stage of biomarker discovery proceedings, investigation depends upon mass spectrometry techniques to make unbiased, semiquantitative analysis of changes between healthy and diseased conditions. The slope of probable biomarkers generated in the discovery stage is to be further substantiated due to the high false positive rate. It is done through  more targeted and quantitative mass spectrometry techniques, such as immuno-affinity peptide enrichment.

This track includes, the latest trends in discovery, development and identification of  biomarkers are discussed. There are many new strategies present  in development of biomarkers. In this section advancements of biomarkers in various sectors like  paediatric diseases biomarkers, clinical biomarkers, and clinical analysis of NGS samples are covered.

  • Track 3-1Protein biomarker discovery
  • Track 3-2Biomarkers for paediatric diseases
  • Track 3-3Clinical biomarker advancements
  • Track 3-4New strategies for discovery
  • Track 3-5Mass spectrometry biomarker discovery
  • Track 3-6New strategies for discovery

Biomarkers plays  an important role in prognosis and diagnosis of various cardiovascular and neurological  diseases. The diseases which are deadly from ages has a possible treatment and easy diagnosis with the help of advancements in biomarkers through different diagnostics methods  and imaging technologies. Cardiac biomarkers and neuro biomarkers has brought a great revolution in disease diagnosis and prognosis. These biomarkers are also used in many other non-cancerous diseases. Some of the important ones are Alzheimer’s disease, cardiovascular diseases, Huntington's disease, Neurodegenerative diseases, Diabetes and  Behcet’s disease.

 

  • Track 4-1Biomarkers for Cardiovascular diseases
  • Track 4-2Biomarkers for Neurodegenerative diseases
  • Track 4-3Biomarkers for diabetes
  • Track 4-4Biomarkers for Behcet s disease
  • Track 4-5Biomarkers for Alzheimer’s
  • Track 4-6Biomarkers for Huntington s disease

The biomarkers used in treatment of cancer is called as cancer biomarkers. Now a days biomarkers plays a crucial role in cancer prognosis, diagnosis and treatment of cancers. Role of biomarkers in cancer research and medicine are Risk assessment, Diagnosis, Prognosis and treatment predictions, Pharmacodynamics and Pharmacokinetics, Monitoring treatment response and Recurrence. There are different types of cancer biomarkers like Prognostic, Pharmacodynamic, Predictive. The major types of cancers in which biomarkers are widely being used in lung cancer, breast cancer, blood cancer, prostate cancer and colorectal cancer. Cancer biomarkers conferences provide a good platform to enhance discussion on various new researches.

 

  • Track 5-1Prognostic cancer biomarker
  • Track 5-2Pharmacodynamic cancer biomarker
  • Track 5-3Predictive cancer biomarker
  • Track 5-4Biomarkers for lung cancer
  • Track 5-5Biomarkers for blood cancer
  • Track 5-6Biomarkers for breast cancer
  • Track 5-7Biomarkers for gastric cancer
  • Track 5-8Biomarkers for colorectal cancer
  • Track 5-9Uses of biomarkers in Cancer research

Biomarkers which are used for clinical purposes are known as clinical biomarkersClinical biomarkers provide a  active  and influential way to understanding the scope of many diseases and   epidemiology random clinical trials, screening for drugs or disease diagnosis and prognosis. It is defined as changes in the constituents of cells or body fluids, these clinical biomarkers offer the means for standardized classification of a disease and risk factors, and that can extend the basic information about the underlying pathogenesis of diseases. The main researches in clinical biomarkers are done in the fields of drug discovery.  pharmacogenomics, oncology,  and disease diagnostics. Classes of Biomarkers in Clinical trails are Safety biomarkers &  Efficacy biomarkers.

 

  • Track 6-1Safety biomarkers
  • Track 6-2Efficacy biomarkers
  • Track 6-3Clinical trails of biomarkers and pharmacogenomics
  • Track 6-4Clinical trails of biomarkers in oncology
  • Track 6-5Clinical trails of biomarkers in diagnostics
  • Track 6-6Clinical trails of biomarkers in drug discovery

Digital biomarkers are used to collect the data about disease management through digital health technologies to predict health-related outcomes. As the role of biosensors, wearables and mobile health in modern healthcare evolves, the potential of digital biomarkers to continually monitor patient health, rapidly diagnose disease, and accurately predict outcomes becomes increasingly apparent. Physiological data may now be collected via digital devices such as portables, wearables, and implantables. It includes electronic medical records such as patient history, medical imaging, genetics, etc. as well as patient-generated data. Digital Biomarkers in drug development.

 

  • Track 7-1Digital Biomarkers in drug development
  • Track 7-2Digital Biomarkers Clinical development
  • Track 7-3Biosensors
  • Track 7-4Applications & Case studies

Biomarker testing or genetic testing is a group of tests that looks for the molecular signs of health so that doctors can treat with best care. Biomarkers, foundation of precision oncology, are very important in management of gastro-esophageal cancer, breast cancer and lung cancer.  Testing practices are intensely deliberated, influencing diagnostic quality and affecting pathologists, oncologists and patients. The advances in biomarker testing are mainly in the fields of cancers in which divided in to Chromosomes tests, Gene tests & Biochemical tests. MicroRNA biomarkers, Insilco biomarkers and several other clinical biomarkers evolved in the recent research have opened to the path for biomarker testing broader.

 

  • Track 8-1Genetic testing
  • Track 8-2Biomarker testing in diagnosis
  • Track 8-3Biomarker testing for cancers
  • Track 8-4Biomarker testing for other diseases

Biomarkers have been classified based on the epidemiological investigations exposure to disease & biomarkers of disease which are also used in the investigation of the natural history and prognosis of a disease. In addition to the factors between exposure and disease, biomarkers have the potential to identify the earliest events in the natural history, reducing the rate of misclassification of both disease and exposure, leads to increase potential mechanisms related to the disease pathogenesis, accounting for some of the variability and effect modification of risk prediction. These epidemiological investigations are one of the reasons behind biomarkers to improve validity while reducing bias in the measurement of exposures (or risk factors) for neurological disease.

 

  • Track 9-1Environmental exposures
  • Track 9-2Effect modifiers
  • Track 9-3Risk factors
  • Track 9-4Screening
  • Track 9-5Diagnostic tests
  • Track 9-6Prognosis

Biomarkers plays   particularly  role in the field of 'personalized medicine'. Moreover, they may be helpful in detecting therapeutic and adverse responses and in patient stratification based on efficacy or safety prediction. Thus, biomarkers are essential tools for the selection of appropriate patients for treatment with certain drugs to and enable personalized medicine, that is 'providing the right treatment to the right patient, at the right dose at the right time'. Prognostic biomarkers are of particular significance for malignant conditions. Similarly, Diagnostic biomarkers are important in autoimmune diseases. Disease severity biomarkers are helpful tools in the treatment for inflammatory skin diseases. Identification, qualification and implementation of the different kinds of biomarkers are challenging and frequently necessitate collaborative efforts.

 

  • Track 10-1Drug development and usage
  • Track 10-2Metabolic Disorders
  • Track 10-3Genetic disorders
  • Track 10-4DNA biomarkers
  • Track 10-5immune disorders

A reliable therapeutic biomarker would facilitate the identity of current management algorithms, ensure that pathogenic mechanisms were eliminated prior to treatment withdrawal, and reduce the frequency of unnecessary sustained therapy. Hence there are various researches in progress to discover new biomarkers for various diseases starting from cardiovascular disorders  to  autoimmune disorders and Genetic disorders.Emerging therapeutic biomarkers in Cancers: Endometrial Cancer, Ovarian cancer, Melanoma, Non-small cell lung cancer, Lung Cancer etc.

  • Track 11-1Melanoma
  • Track 11-2Ovarian cancer
  • Track 11-3Endometrial cancer
  • Track 11-4Lung Cancer
  • Track 11-5Non-small cell lung cancer

Cancer Research

Research in cancer has create different methodologies for analysis, treatment and cure. Research investigations range from the study of disease transmission to the execution of clinical trials and think about utilizations of the different medicines. These applications includes surgery, radiation treatment, chemotherapy, hormone treatment, immunotherapy and advancements in treatment modalities chemo radiotherapy is one of the example which has developed. Beginning in the mid-1990s, the in clinical diseases explorations moved towards treatments derived from biotechnology research, for example, tumor immunotherapy and quality treatment.

  • Track 12-1Radiation treatment
  • Track 12-2Hormone treatment
  • Track 12-3Chemoradiotherapy
  • Track 12-4Tumor immunotherapy

Clinical Research

The Biomarkers discover is major important application in the field of cancer innovations through Biomarker meetings.  Bioethics is a protected innovation which makes to increase the standard of theory regarding clinical approval of biomarkers. Right now use of biomarkers is blasting business. A large portion of the developed associations like Parexel, pfizer and Quintiles are into clinical innovative work. Different types of reporting bias and publication bias, make the association between CRP and prognosis among patients with stable coronary disease one of the most emerging iinovative work by using prognostic biomarker. Publication bias, statistical analytic protocols and registration of studies are one of other measures which might help increase the quality of prognostic biomarker research

  • Track 13-1Bioethics
  • Track 13-2statistical protocols of biomarkers
  • Track 13-3case studies